CLINICAL TRIALS PROFILE FOR COPEGUS

All Clinical Trials for COPEGUS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00018031 ↗	Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2001-06-01	This study will evaluate the safety and effectiveness of combination therapy with peginterferon alfa-2b and ribavirin for treating hepatitis C virus (HCV) infection in HIV-infected patients. In studies of patients with hepatitis C alone, interferon alfa-2b plus ribavirin treatment eradicated the HCV in almost half the patients. Peginterferon alfa-2b is a compound that results from attaching a polyethylene glycol molecule to interferon alfa-2b. This compound stays in the blood longer than unmodified interferon alfa-2b, causing a higher blood concentration and thus maintaining activity against the hepatitis C virus. HIV-infected patients 21 years of age and older with chronic hepatitis C infection and a viral load greater than 2000 copies/mL may be eligible for this 2 1/2-year study. Candidates will be screened with blood and urine tests and possibly a liver biopsy, if a recent one is not available. The liver biopsy is done to determine the severity of liver disease. For this test, patients are admitted to the NIH Clinical Center for 1 to 2 days. A sedative is injected into an arm vein, the skin in the area over the biopsy site is numbed with a local anesthetic, and a needle is inserted rapidly into and out of the liver to obtain a small tissue sample. The patient remains in the hospital overnight for monitoring. A chest X-ray, electrocardiogram (EKG) and liver ultrasound are also done. Within 4 weeks of the screening tests, candidates who appear eligible for the study will have a physical examination, medical history and repeat blood tests. Women who can become pregnant will have serial pregnancy tests throughout the study. Patients who meet the study criteria and decide to participate will begin treatment with weekly injections under the skin of peginterferon alfa-2b and take ribavirin pills twice a day by mouth. In addition, patients will continue to take all other medications prescribed by their doctor. Clinic visits will be scheduled as follows: - Days 1, 3, 5, 7, 10 and 21 - Blood will be drawn for safety tests and to measure blood levels of HIV and HCV. - Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 52, 56 and 64 - Blood and urine tests will be done to determine the side effects of treatment and its effect on the HCV infection. - Week 48 or end of treatment - Treatment will stop after 48 weeks. At this time, or earlier for those who do not complete the 48 weeks, patients will return to the clinic for a routine test.
NCT00056862 ↗	Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	2003-03-01	This study will examine the effectiveness of low-dose peginterferon and ribavirin therapy for certain patients with chronic hepatitis C-a liver disease that, in some patients, can progress to cirrhosis of the liver, liver cancer, and liver failure.
NCT00077636 ↗	ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.	Completed	Hoffmann-La Roche	Phase 4	2003-12-01	This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.
NCT00077649 ↗	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).	Completed	Hoffmann-La Roche	Phase 4	2004-01-01	The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and no prior treatment with interferon. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
NCT00081770 ↗	Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2004-03-01	The objective is to compare the safety and efficacy of the following three treatment regimens in previously untreated adult subjects with chronic hepatitis C infected with Genotype 1: (1) PegIntron 1.5 µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); (2) PegIntron 1µg/kg/wk in combination with weight based REBETOL (800-1400 mg/day); and (3) PEGASYS 180 µg/wk plus COPEGUS 1000-1200 mg/day.
NCT00087594 ↗	A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.	Completed	Hoffmann-La Roche	Phase 4	2003-11-01	This study will evaluate the safety and tolerability of PEGASYS plus ribavirin in previous intravenous (iv) drug users who have CHC and are currently enrolled in a methadone maintenance treatment program. The anticipated time on study treatment is 1-2 years, and the target sample size is

Clinical Trial Conditions for COPEGUS

Condition Name

Condition Name for COPEGUS
Intervention	Trials
Hepatitis C, Chronic	65
Hepatitis C	44
Chronic Hepatitis C	23
Hepatitis C Virus	8

Condition MeSH

Condition MeSH for COPEGUS
Intervention	Trials
Hepatitis C	153
Hepatitis	148
Hepatitis A	127
Hepatitis C, Chronic	102

Clinical Trial Locations for COPEGUS

Trials by Country

Trials by Country for COPEGUS
Location	Trials
Canada	121
Germany	59
Spain	48
France	43
Australia	43

Trials by US State

Trials by US State for COPEGUS
Location	Trials
Texas	73
California	70
New York	60
Florida	58
Virginia	53

Clinical Trial Progress for COPEGUS

Clinical Trial Phase

Clinical Trial Phase for COPEGUS
Clinical Trial Phase	Trials
Phase 4	35
Phase 3	33
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for COPEGUS
Clinical Trial Phase	Trials
Completed	133
Terminated	13
Unknown status	8

Clinical Trial Sponsors for COPEGUS

Sponsor Name

Sponsor Name for COPEGUS
Sponsor	Trials
Hoffmann-La Roche	60
Vertex Pharmaceuticals Incorporated	18
Bristol-Myers Squibb	12

Sponsor Type

Sponsor Type for COPEGUS
Sponsor	Trials
Industry	144
Other	68
NIH	4

COPEGUS Market Analysis and Financial Projection

Last updated: April 28, 2026

Copegus (ribavirin): Clinical Trial Update, Market Analysis, and Projection

Copegus is a brand of ribavirin. It is marketed for viral indications (historically including chronic hepatitis C) and is also used in combination regimens in practice depending on geography, reimbursement, and guideline updates. Patent-driven dynamics are shaped by the age of ribavirin itself (multiple legacy IP estates and broad regulatory history), shifting the market toward generics, biosupply chain economics, and contracting rather than single-product exclusivity.

What is the current clinical development status for Copegus?

Is Copegus still the focus of new interventional trials?

Copegus trials are largely not the dominant source of current ribavirin clinical activity. Most recent published interventional work for ribavirin has moved into:

• Retrofit use in older or rare viral pathways where ribavirin remains clinically relevant
• Combination regimen studies tied to specific viral targets and local guideline gaps
• Safety, dosing optimization, and real-world evidence in populations with constrained alternatives

Because Copegus is a legacy ribavirin brand rather than a new molecular entity, the active pipeline is typically not “Copegus-specific” in the same way as modern branded small molecules. In practice, the more actionable view is ribavirin’s residual clinical role rather than brand-tagged trials.

How do trial patterns affect future uptake?

Key trial-adjacent drivers are:

• Guideline displacement: curative direct-acting antivirals for hepatitis C largely reduced ribavirin’s routine use in many markets.
• Population-specific retention: ribavirin persists in subsets where treatment constraints, resistance, or limited access to DAA regimens drive continued use.
• Cost and access: generic ribavirin availability and tender economics influence whether ribavirin-based combinations remain reimbursed.

Net effect: near-term clinical activity does not appear to be driving a brand-specific resurgence of Copegus; it supports maintenance-level demand where ribavirin remains used.

What is the market reality for ribavirin/Copegus today?

Market structure

Ribavirin is a mature antiviral with:

• Multiple generic entrants across major geographies
• Low price competition constraints determined by procurement and reimbursement
• Limited brand differentiation (Copegus competes primarily on supply reliability and contracting terms)

In ribavirin-led therapeutic areas such as hepatitis C, the market is also heavily influenced by:

• DAA penetration (shifting standard-of-care away from ribavirin)
• Dosing duration and regimen selection across payers and national programs

Value drivers that still matter

Even after DAA displacement, ribavirin demand can persist due to:

• Residual eligibility cohorts for older regimens and constrained access pathways
• Combination protocols where ribavirin is still part of practice in certain settings
• Inventory-based purchasing cycles in institutional markets

Competitive landscape

Competition is dominated by:

• Generic ribavirin manufacturers
• Local tender structures and supply continuity
• Formulation and logistics for oral dosing

Copegus’ practical pricing power is structurally limited, because the active ingredient is widely available.

What market projections can be supported for Copegus/Copegus-relevant ribavirin demand?

Core projection thesis

For a legacy ribavirin brand, market projections typically track:

1. Declining or flat demand in hepatitis C as DAA regimens continue to expand
2. Stable niche demand where ribavirin remains used due to access, eligibility, or specific protocols
3. Margin compression driven by generic competition and tender pricing

Projection ranges (directional)

The most supportable forward-looking view for Copegus (brand) is:

• Revenue: likely low growth to declining in mature markets due to generic substitution and guideline displacement.
• Volumes: likely flat to down overall, with regional variation depending on national treatment program maturity and access to DAAs.
• Earnings: constrained by contracting intensity and pricing pressure; outcomes depend on supply agreements and local channel strategy.

Scenario framing that maps to decision-making

Use three operating scenarios for planning:

Base case

• Hepatitis C cure rates continue to shift standard-of-care away from ribavirin.
• Remaining demand stays niche and procurement-led.
• Copegus maintains presence through contracting but does not regain category share.

Downside case

• Additional payer and national program restrictions on ribavirin combinations.
• Greater tender price pressure accelerates.
• Copegus loses share in institutional channels.

Upside case

• Regional access bottlenecks slow DAA exclusivity penetration and sustain combination protocols longer.
• Copegus holds supply positions via framework agreements.

How do patents and exclusivity affect Copegus economics?

Is there meaningful remaining brand-level exclusivity?

Copegus is ribavirin, and the molecule is mature. That makes brand-level exclusivity less likely to be a primary growth lever. Economic outcomes rest on:

• Generic encroachment timelines
• Packaging/labeling and local registrations
• Contract awards and procurement switching costs
• Manufacturing scale and supply continuity

Where is Copegus likely to hold demand pockets?

Copegus-linked ribavirin demand tends to concentrate in:

• Countries with staged DAA rollout or payer restrictions that keep combination regimens in place longer
• Subpopulations where alternative regimens are constrained by eligibility, resistance patterns, or clinical policy
• Institutions with existing procurement frameworks for ribavirin-based regimens

This is a channel-and-program story more than a new-trial story.

Competitive and commercial implications for R&D and investment

If you are evaluating partnering or late-stage R&D

For ribavirin/Copegus, the highest-value “innovation” is unlikely to be new trials for the same molecule in the same broad indication. The more realistic investment lens is:

• New combinations or refined clinical use cases that create differentiated reimbursement value
• Formulation or supply-chain improvements that improve contracting outcomes
• Evidence packages that support protocol inclusion in constrained settings

If you are modeling market entry for a generic

The practical levers are:

• Manufacturing cost-down and quality systems
• Stability and supply commitments
• Contracting strategy in tender-heavy geographies

Key Takeaways

• Copegus (ribavirin) sits in a mature antiviral category where new interventional activity is not brand-driving.
• The market is shaped by DAA displacement in hepatitis C, leaving ribavirin demand concentrated in niche cohorts and procurement-led settings.
• Forward projections are best framed as flat-to-declining volumes with margin pressure, with upside tied to regional access constraints and channel retention rather than new clinical breakthroughs.
• Decision-making should prioritize contract dynamics, supply positioning, and reimbursement protocols over patent-led expectations.

FAQs

1) What is Copegus’ active ingredient and typical use context?

Copegus is ribavirin, used in antiviral regimens where ribavirin remains clinically used, historically including hepatitis C in combination settings.

2) Why does DAA adoption reduce ribavirin demand?

DAAs are curative for hepatitis C for most patient groups, which reduces reliance on ribavirin-containing regimens and lowers overall ribavirin utilization.

3) Are there still meaningful clinical trials for ribavirin?

Interventional activity exists for ribavirin in more limited or specialized contexts, but it is less likely to be concentrated on Copegus as a brand rather than on ribavirin within specific clinical protocols.

4) What determines Copegus revenue more than clinical efficacy?

Procurement pricing, tender wins, reimbursement coverage, and guideline inclusion determine whether Copegus is selected in institutional and payer channels.

5) What is the most realistic market projection for the next few years?

A base case of low growth to decline for the branded product is most consistent with generic competition and guideline displacement, with regional variability depending on DAA access and continued use of combination protocols.

---

References

[1] FDA. Copegus (ribavirin) prescribing information. U.S. Food and Drug Administration.
[2] EMA. Copegus (ribavirin) product information. European Medicines Agency.
[3] World Health Organization. Guidelines for the care and treatment of persons with hepatitis C virus infection. WHO.
[4] AASLD/IDSA. Hepatitis C guidance and updates on treatment regimens. American Association for the Study of Liver Diseases / Infectious Diseases Society of America.